Go Pro
→ Bank of America: 'Digital Dollar Inevitable' (From Decentralized Masters) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
$0.00
-60.0%		$0.03
$0.00
▼
$0.11
$27K-0.5329,684 shs16,009 shs
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$0.00
-36.4%		$0.00
$0.00
▼
$0.30
$29K-9.0259,439 shs1,300 shs
Shineco stock logo
SISI
Shineco
$0.11
$0.01
$0.00
▼
$6.79
$44K-1.761,989 shs80 shs
Trevena, Inc. stock logo
TRVN
Trevena
$0.01
$0.00
$0.00
▼
$1.50
$11K-0.55726 shs44 shs
10 Best Stocks to Own - Fall 2026 Cover
10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.00%+400.00%-98.49%-98.82%-99.16%
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
-36.36%-12.50%-69.57%-91.36%-99.75%
Shineco stock logo
SISI
Shineco
0.00%+52,400.00%+34,900.00%+4,900.00%-98.37%
Trevena, Inc. stock logo
TRVN
Trevena
0.00%+2,700.00%+1,020.00%+646.67%+12.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
$0.00
-60.0%		$0.03
$0.00
▼
$0.11
$27K-0.5329,684 shs16,009 shs
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$0.00
-36.4%		$0.00
$0.00
▼
$0.30
$29K-9.0259,439 shs1,300 shs
Shineco stock logo
SISI
Shineco
$0.11
$0.01
$0.00
▼
$6.79
$44K-1.761,989 shs80 shs
Trevena, Inc. stock logo
TRVN
Trevena
$0.01
$0.00
$0.00
▼
$1.50
$11K-0.55726 shs44 shs
10 Best Stocks to Own - Fall 2026 Cover
10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.00%+400.00%-98.49%-98.82%-99.16%
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
-36.36%-12.50%-69.57%-91.36%-99.75%
Shineco stock logo
SISI
Shineco
0.00%+52,400.00%+34,900.00%+4,900.00%-98.37%
Trevena, Inc. stock logo
TRVN
Trevena
0.00%+2,700.00%+1,020.00%+646.67%+12.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.00
N/AN/AN/A
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
1.00
SellN/AN/A
Shineco stock logo
SISI
Shineco
1.00
SellN/AN/A
Trevena, Inc. stock logo
TRVN
Trevena
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/A$0.71 per shareN/A
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$10.77M0.00N/AN/A($0.67) per share0.00
Shineco stock logo
SISI
Shineco
$9.60M0.00N/AN/A$4,679.15 per share0.00
Trevena, Inc. stock logo
TRVN
Trevena
$443K0.02N/AN/A($11.07) per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
-$16.08M-$1.09N/AN/AN/AN/A-2,842.40%-337.48%11/12/2026 (Estimated)
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
-$60.48M$0.730.00N/AN/A-254.28%N/A-192.17%11/5/2026 (Estimated)
Shineco stock logo
SISI
Shineco
-$22.45M-$204.00N/AN/AN/A-380.55%-79.89%-33.01%N/A
Trevena, Inc. stock logo
TRVN
Trevena
-$40.29M-$47.04N/AN/AN/AN/AN/A-119.55%11/5/2026 (Estimated)
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/AN/A
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
N/AN/AN/AN/AN/A
Shineco stock logo
SISI
Shineco
N/AN/AN/AN/AN/A
Trevena, Inc. stock logo
TRVN
Trevena
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/A
0.86
0.86
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
N/A
0.48
0.48
Shineco stock logo
SISI
Shineco
N/A
0.72
0.71
Trevena, Inc. stock logo
TRVN
Trevena
N/A
2.42
2.42

Institutional Ownership

CompanyInstitutional Ownership
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
5.74%
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
44.27%
Shineco stock logo
SISI
Shineco
4.08%
Trevena, Inc. stock logo
TRVN
Trevena
13.56%

Insider Ownership

CompanyInsider Ownership
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.72%
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
6.90%
Shineco stock logo
SISI
Shineco
0.02%
Trevena, Inc. stock logo
TRVN
Trevena
2.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
1053.90 million5.73 millionNo Data
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
2041.85 million38.91 millionNo Data
Shineco stock logo
SISI
Shineco
119415,000415,000Not Optionable
Trevena, Inc. stock logo
TRVN
Trevena
23959,000841,000No Data

Recent News About These Companies

Trevena stock holds near its yearly range as trading data reset
September 22 at 9:00 AM  |  ad-hoc-news.deA
Trevena (NASDAQ:TRVN) Share Price Passes Below 200-Day Moving Average - Should You Sell?
September 18, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31029997
Trevena Inc.
May 27, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/TRVN/financials
Trevena Restructures China Royalty Rights to Exit Debt
January 14, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/trevena-restructures-china-royalty-rights-to-exit-debt?utm_source=marketbeat.com&utm_medium=referral
Softball: Conrad Weiser’s Alex Trevena earns statewide player of the year award; 5 other Berks players honored
July 8, 2025  |  msn.comhttps://www.msn.com/en-us/sports/mlb/softball-conrad-weiser-s-alex-trevena-earns-statewide-player-of-the-year-award-5-other-berks-players-honored/ar-AA1IcIZz
Trevena, Inc. (TRVN) - Yahoo Finance
June 29, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/quote/TRVN/press-releases/
Trevena Enters Securities Exchange Agreement with Investor
May 15, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/trevena-enters-securities-exchange-agreement-with-investor?utm_source=marketbeat.com&utm_medium=referral
Berks sports roundup: Alex Trevena helps Conrad Weiser to 8-5 softball win
April 11, 2025  |  readingeagle.comR
Vanessa Hudgens and Oliver Trevena Appear at Expo West for Caliwater
March 9, 2025  |  msn.comhttps://www.msn.com/en-us/music/news/vanessa-hudgens-and-oliver-trevena-appear-at-expo-west-for-caliwater/ar-AA1Axb5h
JMP Securities downgrades Trevena (TRVN) to a Hold
December 27, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/jmp-securities-downgrades-trevena-trvn-to-a-hold-1034177267
‘Plane’ Actor Oliver Trevena Signs With Untitled Entertainment
December 16, 2024  |  yahoo.comhttps://www.yahoo.com/entertainment/plane-actor-oliver-trevena-signs-153000870.html
Lyme Regis town councillor John Trevena stand down
December 11, 2024  |  bridportnews.co.ukB
Trevena (TRVN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
December 10, 2024  |  zacks.comhttps://www.zacks.com/stock/news/2381592/trevena-trvn-could-find-a-support-soon-here-s-why-you-should-buy-the-stock-now?cid=cs-stocknewsapi-ft-tale_of_the_tape|hammer_chart_pattern_(ta)-2381592
Trevena appoints new financial chief
November 29, 2024  |  investing.comhttps://www.investing.com/news/sec-filings/trevena-appoints-new-financial-chief-93CH-3745129
Trevena Appoints Katrine Sutton as New CFO
November 27, 2024  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/trevena-appoints-katrine-sutton-as-new-cfo?utm_source=marketbeat.com&utm_medium=referral
HC Wainwright & Co. Downgrades Trevena (TRVN)
November 16, 2024  |  msn.comhttps://www.msn.com/en-us/money/topstocks/hc-wainwright-co-downgrades-trevena-trvn/ar-AA1u9FYi
Trevena, Inc. Navigates Financial Challenges and Strategic Changes
November 9, 2024  |  msn.comhttps://www.msn.com/en-us/money/companies/trevena-inc-navigates-financial-challenges-and-strategic-changes/ar-AA1tMJqv
Chester County biopharm firm's latest layoffs impact its C-suite
November 7, 2024  |  bizjournals.comhttps://www.bizjournals.com/philadelphia/news/2024/11/07/trevena-chesterbrook-layoffs-c-suite-pain-medicine.html
Trevena teeters in dangerous territory, terminating CEO and other execs amid strategic review
November 7, 2024  |  fiercebiotech.comF
Trevena Reports Third Quarter 2024 Results and Provides Business Update
November 7, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/11/07/2976530/0/en/trevena-reports-third-quarter-2024-results-and-provides-business-update.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bio-Path stock logo

Bio-Path NASDAQ:BPTH

$0.0002 0.00 (-60.00%)
As of 10:57 AM Eastern

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.

Carisma Therapeutics stock logo

Carisma Therapeutics NASDAQ:CARM

$0.0007 0.00 (-36.36%)
As of 12:31 PM Eastern

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Shineco stock logo

Shineco NASDAQ:SISI

$0.10 0.00 (0.00%)
As of 09/23/2026

Shineco, Inc., through its subsidiaries, processes and distributes agricultural produce. It also engages in the growing and cultivation of mulberry trees and silkworm cocoons; distribution of fruit business; and processing and distribution of silk and silk fabrics, as well as other by-products. The company was incorporated in 1997 and is headquartered in Beijing, the People's Republic of China.

Trevena stock logo

Trevena NASDAQ:TRVN

$0.01 0.00 (0.00%)
As of 09/23/2026

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas